GSK PLC (GSK) is a Zacks Rank #5 (Strong Sell) after the company beat the Zacks Consensus Estimate when the last reported. The company is in the healthcare space and there has been a lot of press ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100's ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...

Symphony Ltd (BOM:517385) reports a 49% increase in standalone top line and announces strategic measures to tackle forex losses and doubtful debts.

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

A task force has been set up to look into how to spend a £2m GSK legacy as the pharmaceutical giant closes its doors in Ulverston. Giles ...

Trials in China usually recruit patients faster than in the west because of the country’s large pool of people who have not yet taken drugs for their condition and who are keen to participate in ...

The stock market extended its winning streak on Wednesday, closing firmer as investors seemed to have already priced in the ...

Adding exposure away from the 'Magnificent Seven' can lower your portfolio risk, and you can earn high dividend yields at the same time The S&P 500's weighting by market capitalization has led to a ...

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance ...